ABSTRACT
The design and synthesis of a new series of potent non-prostanoid IP receptor agonists that showed oral efficacy in the rat monocrotaline model of pulmonary arterial hypertension (PAH) are described. Detailed profiling of a number of analogues resulted in the identification of 5c (ralinepag) that has good selectivity in both binding and functional assays with respect to most members of the prostanoid receptor family and a more modest 30- to 50-fold selectivity over the EP3 receptor. In our hands, its potency and efficacy are comparable or superior to MRE269 (the active metabolite of the clinical compound NS-304) with respect to in vitro IP receptor dependent cAMP accumulation assays. 5c had an excellent PK profile across species. Enterohepatic recirculation most probably contributes to a concentration-time profile after oral administration in the cynomolgus monkey that showed a very low peak-to-trough ratio. Following the identification of an acceptable solid form, 5c was selected for further development for the treatment of PAH.
Subject(s)
Acetates/therapeutic use , Carbamates/therapeutic use , Hypertension, Pulmonary/drug therapy , Receptors, Prostaglandin/agonists , Acetates/pharmacokinetics , Administration, Oral , Animals , Biological Availability , Carbamates/pharmacokinetics , Drug Discovery , Rats , Structure-Activity RelationshipABSTRACT
The design and optimization of a novel trans-1,4-dioxycyclohexane GPR119 agonist series is described. A lead compound 21 was found to be a potent and efficacious GPR119 agonist across species, and possessed overall favorable pharmaceutical properties. Compound 21 demonstrated robust acute and chronic regulatory effects on glycemic parameters in the diabetic or non-diabetic rodent models.
Subject(s)
Cyclohexanes/chemistry , Cyclohexanes/therapeutic use , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/therapeutic use , Receptors, G-Protein-Coupled/agonists , Administration, Oral , Animals , Blood Glucose/analysis , Cyclohexanes/administration & dosage , Cyclohexanes/pharmacokinetics , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/metabolism , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/pharmacokinetics , Male , Mice , Rats, Sprague-Dawley , Rats, Zucker , Receptors, G-Protein-Coupled/metabolism , Structure-Activity RelationshipABSTRACT
The design and synthesis of two closely related series of prostacyclin receptor agonist compounds that showed excellent human IP receptor potency and efficacy is described. Compounds from this series showed in vivo activity after SC dosing in the monocrotaline model of PAH in rat.
Subject(s)
Drug Discovery , Hypertension, Pulmonary/drug therapy , Receptors, Prostaglandin/agonists , Animals , Humans , Hypertension, Pulmonary/chemically induced , Monocrotaline , Platelet Aggregation/drug effects , Rats , Receptors, Prostaglandin/metabolismABSTRACT
A series of 5-fluoro-4,6-dialkoxypyrimidine GPR119 modulators were discovered and optimized for in vitro agonist activity. A lead molecule was identified that has improved agonist efficacy relative to our clinical compound (APD597) and possesses reduced CYP2C9 inhibitory potential. This optimized lead was found to be efficacious in rodent models of glucose control both alone and in combination with a Dipeptidyl peptidase-4 (DPP-4) inhibitor.